GLP-1 receptor agonist: difference between revisions
Diff·revision 23 → 24·17:33, 5 May 2025
Difference between revision 23 and revision 24 of GLP-1 receptor agonist. 6 lines changed; the page grew by 504 bytes.
| Revision 23 — 17:34, 10 Apr 2025 AxisLabelAgda (talk) split §Pharmacology into receptor binding and downstream signalling 9,254 bytes ±0 | Revision 24 — 17:33, 5 May 2025 PurityClaimPia (talk) state plainly that the research-use-only form is not approved for human use 9,758 bytes +504 | ||
|---|---|---|---|
| 58 | Less common but clinically significant concerns include gallbladder disease, acute pancreatitis, and — on the basis of rodent carcinogenicity data — a labelled contraindication in people with a personal or family history of medullary thyroid carcinoma. Delayed gastric emptying has prompted revised guidance on [[Aspiration risk under anaesthesia|preoperative fasting]].{{r|nauck2016}} | 58 | Less common but clinically significant concerns include gallbladder disease, acute pancreatitis, and — on the basis of rodent carcinogenicity data — a labelled contraindication in people with a personal or family history of medullary thyroid carcinoma. Delayed gastric emptying has prompted revised guidance on [[Aspiration risk under anaesthesia|preoperative fasting]].{{r|nauck2016}} |
| 59 | 59 | ||
| + | 60 | Loss of lean mass accompanies the loss of fat mass, in a proportion broadly comparable with that seen in other forms of substantial caloric restriction. Whether this proportion is materially different from that of diet-induced weight loss is disputed, and the trials were not designed to settle it.{{r|wilding2021}} | |
| + | 61 | ||
| 60 | == References == | 62 | == References == |
| 61 | {{reflist}} | 63 | {{reflist}} |
| ⋮ | ⋮ | ||
| 67 | <ref name="frias2023">Frías JP, Hsia S, Eyde S, et al. "Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a phase 2 randomised trial." ''The Lancet'' 402(10400):472–483 (2023). PMID 37369232.</ref> | 69 | <ref name="frias2023">Frías JP, Hsia S, Eyde S, et al. "Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a phase 2 randomised trial." ''The Lancet'' 402(10400):472–483 (2023). PMID 37369232.</ref> |
| 68 | 70 | ||
| + | 71 | == Further reading == | |
| + | 72 | * Müller TD, Finan B, Bloom SR, et al. "Glucagon-like peptide 1 (GLP-1)." ''Molecular Metabolism'' 30:72–130 (2019). | |
| + | 73 | ||
| 69 | == See also == | 74 | == See also == |
| 70 | * [[Glucagon-like peptide-1]] | 75 | * [[Glucagon-like peptide-1]] |
| ⋮ | ⋮ | ||
| 74 | * [[Liraglutide]] | 79 | * [[Liraglutide]] |
| 75 | * [[Adverse effects of GLP-1 receptor agonists]] | 80 | * [[Adverse effects of GLP-1 receptor agonists]] |
| + | 81 | * [[Comparison of GLP-1 receptor agonists]] | |
| 76 | 82 | ||
| 77 | {{DEFAULTSORT:GLP-1 receptor agonist}} | 83 | {{DEFAULTSORT:GLP-1 receptor agonist}} |